Rubella
68
1
1
54
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Published Results
28 trials with published results (41%)
Research Maturity
54 completed trials (79% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
4.4%
3 terminated out of 68 trials
94.7%
+8.2% vs benchmark
66%
45 trials in Phase 3/4
52%
28 of 54 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 54 completed trials
Clinical Trials (68)
Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections
Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age
Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months
Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination
Co-administration Study of OCV, TCV and MR
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines
Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial
The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine
Measles, Mumps, and Rubella (MMR) Immunity in College Students
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine
Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)